Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Parexel International Corporation, commonly known as Parexel, is a leading global biopharmaceutical services provider headquartered in the United States. Founded in 1983, the company has established a strong presence in key operational regions, including Europe and Asia, delivering innovative solutions across the clinical research and regulatory consulting sectors.
Specialising in drug development and regulatory affairs, Parexel offers a comprehensive suite of services that includes clinical trial management, biostatistics, and market access strategies. What sets Parexel apart is its commitment to advancing the development of new therapies while ensuring compliance with regulatory standards.
With a robust market position, Parexel has achieved numerous milestones, including recognition for its excellence in clinical research. The company continues to play a pivotal role in the biopharmaceutical industry, helping clients navigate the complexities of bringing new drugs to market efficiently and effectively.
+36 vs industry average
Parexel’s score of 68 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has below-average carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
In 2025, Parexel International Corporation reported total carbon emissions of approximately 337.8 million kg CO2e. This figure includes Scope 1 emissions of about 2.3 million kg CO2e, Scope 2 emissions of approximately 4.5 million kg CO2e, and significant Scope 3 emissions amounting to about 330.9 million kg CO2e. The company has set ambitious targets to reduce its greenhouse gas emissions, aiming for a 42% reduction in absolute Scope 1 emissions and a 25% reduction in absolute Scope 3 emissions by 2030, using 2022 as the base year.
In 2024, Parexel's total emissions were approximately 323.4 million kg CO2e, with Scope 1 emissions at about 2.7 million kg CO2e, Scope 2 emissions at approximately 5.9 million kg CO2e, and Scope 3 emissions reaching about 314.8 million kg CO2e. The trend indicates a commitment to reducing emissions across all scopes, with a focus on sustainable practices.
The company is also committed to sourcing 100% renewable electricity through 2030, reinforcing its dedication to sustainability. These targets align with the Science Based Targets initiative (SBTi) and reflect Parexel's commitment to achieving net-zero emissions by 2050. The emissions data is not cascaded from any parent company, indicating that these figures are independently reported by Parexel International Corporation.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 1
Parexel International Corporation commits to reduce absolute scope 1 GHG emissions 42% by 2030 from 2022 base year. Parexel International Co…
2030
25% reduction in scope 3 total
Parexel International Corporation commits to reduce absolute scope 1 GHG emissions 42% by 2030 from 2022 base year. Parexel International Co…
2030
42% reduction in Scope 2
Parexel International Corporation commits to reduce absolute scope 1 GHG emissions 42% by 2030 from 2022 base year. Parexel International Co…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


Common questions about Parexel’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more